Recent progress in rational drug design of neuraminidase inhibitors
Yu Liu1, Jie Zhang, Wenfang Xu
1Department of Medicinal Chemistry, School of Pharmaceutical Sciences, ShanDong University, 44, West Wenhua Road, 250012, Ji'nan, ShanDong, PR China. liuyu1984@mail.sdu.edu.cn
Abstract:
Neuraminidase is a major glycoprotein of influenza virus which is essential for viral infection and offers a potential target for antiviral drug development. Rational drug design of NA inhibitors is now in the clinic and these molecules are effective and safe for the treatment of influenza. Recently, research of structure-based NA inhibitors is becoming an interesting field, leading to a breakthrough in the control of influenza. Here we review the progress in the rational drug design of NA inhibitors in recent years.
Related Concept Videos
Inhibitors Of Virion Release
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Antiviral Nucleoside Inhibitors


